A phase I study to assess the safety, tolerability, and pharmacokinetics of enteric-coated buprenorphine (BuTab) in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2016
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid abuse; Pain
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors Relmada Therapeutics
- 11 Jan 2016 Top-line results will be presented at 2016 Biotech Showcase™ in San Francisco Presentation on January 13, 2016, as per Relmada Therapeutics media release.
- 08 Dec 2015 According to Relmada Therapeutics media release, positive topline results of oral formulation of buprenorphine were announced.
- 07 Dec 2015 According to a Relmada Therapeutics media release, data from this study are expected before the end of 2015.